Neos Therapeutics, Inc.

Neos Therapeutics, Inc. (NEOS) relating to its proposed merger with Aytu BioScience, Inc. Under the terms of the agreement, NEOS shareholders will receive 0.1088 shares of Aytu per share they own.

Perspecta, Inc.

Perspecta, Inc. (PRSP) relating to its proposed acquisition by affiliates of Peraton. Under the terms of the agreement, PRSP shareholders will receive $29.35 in cash per share they own.

Jaws Acquisition Corp.

Jaws Acquisition Corp. (JWS) relating to its proposed merger with Cano Health, LLC. Under the terms of the agreement, JWS will acquire Cano Health through a reverse merger, with Cano Health emerging as a publicly traded company.

GX Acquisition Corp.

GX Acquisition Corp. (GXGX) relating to its proposed merger with Celularity, Inc. Under the terms of the agreement, GXGX will acquire Celularity through a reverse merger, with Celularity emerging as a publicly traded company.

TC PipeLines, LP

TC PipeLines, LP (TCP) relating to its proposed acquisition by TC Energy Corporation (“TRP”). and its affiliated companies. Under the terms of the agreement, TCP unitholders will receive 0.70 shares of TRP for each unit they hold.

MGP Ingredients, Inc.

MGP Ingredients, Inc. (MGPI) relating to its proposed acquisition of Luxco, Inc. and its affiliated companies. Under the terms of the agreement, Luxco shareholders will collectively receive an aggregate cash consideration estimated at $238 million and be issued 5.0 million shares of MGP common stock.

Thunder Bridge Acquisition II, Ltd.

Thunder Bridge Acquisition II, Ltd. (THBR) relating to its proposed merger with indie Semiconductor. Under the terms of the agreement, THBR will acquire Semiconductor through a reverse merger, with Semiconductor emerging as a publicly traded company.

QEP Resources, Inc.

QEP Resources, Inc. (QEP) relating to its proposed acquisition by Diamondback Energy, Inc. Under the terms of the agreement, QEP shareholders will receive 0.05 shares of Diamondback common stock per share they own.

Obalon Therapeutics, Inc.

Obalon Therapeutics, Inc. (OBLN) relating to its proposed merger with ReShape Lifesciences, Inc. Under the terms of the agreement, OBLN will merge with and into ReShape, with ReShape emerging as a publicly traded company.

RealPage, Inc.

RealPage, Inc. (RP) relating to its proposed acquisition by affiliates of Thoma Bravo, L.P. Under the terms of the agreement, RP shareholders will receive $88.75 in cash per share they own.